TECHNOLOGY

Multi-specific Ab platform technology

Protein Structure & immunology based drug design


Multi mode of action to address unmet medical needs(safety & efficacy)


PG-12

Bispecific Ab for SBS patients



● Dual MoA: gut targeting & enhancement of intestine function.
● Designed to be First-in-Class bispecific glucagon like peptide analogous for weaning-off the PN/IV from SBS-IF patients
● Primary end point : ≥70% TPN discontinuation
● Target indication : 1st adult SBS, 2nd pediatric SBS & NASH

※ MoA: Mode of Action, API: Active Pharmaceutical Ingredient, SBS: short bowel syndrome
※ PN/IV: Parenteral nutrition (PN) is the feeding of a person intravenously, SBS-IF: SBS with intestinal failure
※ TPN: total parenteral nutrition, NASH: non-alcoholic steatohepatitis


PG-12

Bispecific Ab for SBS patients


● Dual MoA: gut targeting & enhancement of intestine function
● Designed to be First-in-Class bispecific glucagon like peptide analogous for weaning-off the PN/IV from SBS-IF patients
● Primary end point : ≥70% TPN discontinuation
● Target indication : 1st adult SBS, 2nd pediatric SBS & NASH

※ MoA: Mode of Action, API: Active Pharmaceutical Ingredient, SBS: short bowel syndrome
※ PN/IV: Parenteral nutrition (PN) is the feeding of a person intravenously, SBS-IF: SBS with intestinal failure
※ TPN: total parenteral nutrition, NASH: non-alcoholic steatohepatitis

PG-51

Bispecific Ab for CU patients



● Dual MoA: effectively suppresses allergic reactions by blocking IgE and modulating immunity
● Designed to be First-in-Class bispecific therapeutic for the treatment of IgE-mediated allergy, such as chronic urticarial and food allergy.
● Primary end point : No itch, no hives and no anaphylaxis
● Target indication : 1st CU, 2nd Food allergy, 3rd : Asthma

※ API: Active Pharmaceutical Ingredient
※ CU: chronic urticaria
※ IgE: immunoglobulin E


PG-51

Bispecific Ab for CU patients


● Dual MoA: effectively suppresses allergic reactions by blocking IgE and modulating immunity
● Designed to be First-in-Class bispecific therapeutic for the treatment of IgE-mediated allergy, such as chronic urticarial and food allergy.
● Primary end point : No itch, no hives and no anaphylaxis
● Target indication : 1st CU, 2nd Food allergy, 3rd : Asthma

※ API: Active Pharmaceutical Ingredient
※ CU: chronic urticaria
※ IgE: immunoglobulin E